ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2013
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Pooled it
- Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).American journal of hematology · 2021Trial
- A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.Pharmacotherapy · 2016Trial
- Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.Medical oncology (Northwood, London, England) · 2014Trial
- AnemiaScore: An Investigator-Developed Rule-Based Clinical Decision-Support Framework for Cancer-Related Anemia-A Single-Center Retrospective Proof-of-Concept Concordance Study.Diagnostics (Basel, Switzerland) · 2026Article
- Management of iron deficiency anemia and the role of intravenous iron supplementation in patients undergoing cancer chemotherapy: a real-world retrospective study in Japan.International journal of clinical oncology · 2026Observational
- Navigating Anemia in Solid and Hematologic Malignancies: A Comprehensive Review of Classical and Emerging Therapies.European journal of haematology · 2026Review
- Article
- Review
- Evaluation of a Quality-Improvement Initiative to Address Nutritional Anemia in Gynecologic Oncology.O&G open · 2025Article
- Prevalence of functional iron deficiency in patients with malignancies and its impact on fatigue-specific quality of life.ESMO real world data and digital oncology · 2025Article
- Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia.International journal of molecular sciences · 2025Article
- Decoding iron deficiency in cancer: mechanisms, immune modulation, and therapeutic potential.Frontiers in nutrition · 2025Review
- Functional iron deficiency anemia in patients with cancer.Blood research · 2024Review
- Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study.Therapeutic advances in medical oncology · 2024Article
- Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia.Current oncology (Toronto, Ont.) · 2023Article
- How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.European journal of medical research · 2023Review
- Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease.Frontiers in pediatrics · 2022Article
- Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.Scientific reports · 2021Observational
- Flipside of the Coin: Iron Deficiency and Colorectal Cancer.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous (i.v.) iron can improve anaemia of chronic disease and response to erythropoiesis-stimulating agents (ESAs), but data on its use in practice and without ESAs are limited. This study evaluated effectiveness and tolerability of ferric carboxymaltose (FCM) in routine treatment of anaemic cancer patients. PATIENTS AND
methodsOf 639 patients enrolled in 68 haematology/oncology practices in Germany, 619 received FCM at the oncologist's discretion, 420 had eligible baseline haemoglobin (Hb) measurements, and 364 at least one follow-up Hb measurement. Data of transfused patients were censored from analysis before transfusion.
resultsThe median total iron dose was 1000 mg per patient (interquartile range 600-1500 mg). The median Hb increase was comparable in patients receiving FCM alone (1.4 g/dl [0.2-2.3 g/dl; N = 233]) or FCM + ESA (1.6 g/dl [0.7-2.4 g/dl; N = 46]). Patients with baseline Hb up to 11.0 g/dl and serum ferritin up to 500 ng/ml benefited from FCM treatment (stable Hb ≥ 11.0 g/dl). Also patients with ferritin >500 ng/ml but low transferrin saturation benefited from FCM treatment. FCM was well tolerated, 2.3% of patients reported putative drug-related adverse events.
conclusionsThe substantial Hb increase and stabilisation at 11-12 g/dl in FCM-treated patients suggest a role for i.v. iron alone in anaemia correction in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.